source
- Daiichi Sankyo postpones annual results, stock dipsDaiichi Sankyo has pushed back the reporting of its annual results, saying it needs more time to finalize the numbers. The Japanese company had intended to unveil its financials for its fiscal year…Endpoints · 3mo ago↗ source
- FDA approves Regeneron’s hearing loss gene therapyOtarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…BioPharma Dive · 3mo ago↗ source
- FDA approves Regeneron's hearing loss gene therapy OtarmeniRegeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...